Double-Barreled attack: stem cell transplant + CAR-T therapy targets tough myeloma

NCT ID NCT05632380

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times

Summary

This study tests a powerful two-step treatment for people with an aggressive form of multiple myeloma that didn't respond well to first-line therapy. First, patients receive their own stem cells (a stem cell transplant), followed by an infusion of their own genetically modified immune cells (C-CAR088 CAR-T cells) designed to find and kill myeloma cells. The goal is to see if this combination is safe and can achieve deep, lasting remission in 20 participants aged 18 to 65.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of Hematology & Blood Diseases Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA